During the past decade, CAMC Health Education and Research Institute conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 9 clinical trials were completed, i.e. on average, 90% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CAMC Health Education and Research Institute" #1 sponsor was "Acorda Therapeutics" with 3 trials, followed by "C. R. Bard" with 3 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "NSABP Foundation Inc" with 2 trials sponsored and "W.L.Gore & Associates" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CAMC Health Education and Research Institute" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "US Oncology Research" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "CAMC Health Education and Research Institute" are "Peripheral Arterial Disease" (3 trials), "Breast Cancer" (2 trials), "Multiple Sclerosis" (2 trials), "AKI (Acute Kidney Injury) Due to Trauma" (1 trials) and "Aortic Aneurysm, Abdominal" (1 trials). Many other conditions were trialed in "CAMC Health Education and Research Institute" in a lesser frequency.

Most popular intervention types in "CAMC Health Education and Research Institute" are "Drug" (12 trials), "Device" (10 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Fampridine-SR" (3 trials), "Atezolizumab" (1 trials), "BARD LifeStent" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "CAMC Health Education and Research Institute" are 22 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "CAMC Health Education and Research Institute". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in CAMC Health Education and Research Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CAMC Health Education and Research Institute, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 7 trials that are defined as “Not Applicable".